Selective Serotonin Reuptake Inhibitors (SSRIs) are a class of drugs commonly prescribed as antidepressants and anxiolytics. While mainstream psychiatry often views depression as the result of a "chemical imbalance" (specifically a lack of serotonin, frequently mischaracterized as the "happy hormone"), the bioenergetic perspective offers a diametrically opposed view.

SSRIs
Formula N/A
Class
Administration Oral
Solubility
Legal status Rx
Brand names Zoloft, Lexapro, Prozac, Celexa, Paxil, Luvox
Bioavailability
Recommended dose N/A
Upper limit N/A
LD50
Ray's verdict Generally hurts
Not safe to supplement

According to Ray Peat, serotonin is a hormone of stress, hibernation, and metabolic suppression. In this framework, SSRIs, by increasing serotonin concentration in the synaptic cleft, do not correct a deficiency. Instead, they can exacerbate metabolic stress, reduce cellular energy production (mitochondrial respiration), and act synergistically with estrogen and prolactin.[1][2]

Uncontrolled serotonin is a major factor in destructive, seemingly uncontrolled aggression…. inclinations of the same sort when combined with social and economic power… become potentially world destroying

— Ray Peat[3]

11.4% of U.S. adults have taken prescription medication for depression in the last 12 months.[4][5]

More in Serotonin

Structure / Chemical properties

[edit]

Unlike some other drug classes, SSRIs do not share a uniform chemical structure. They are primarily defined by their pharmacological activity: their ability to bind to the serotonin transporter (SERT) and inhibit its action.

However, it is notable that many of them contain halogen atoms (such as fluorine in fluoxetine or chlorine in sertraline).

From a bioenergetic standpoint, this can contribute to their toxicity and their interference with thyroid function, as halogens can compete with iodine and disrupt thyroid hormone synthesis.

Function / Mechanism of action

[edit]

CUMS-depression rodent data suggest SSRI benefit may parallel progesterone through shared TNF-α suppression rather than sustained extracellular serotonin elevation.[6] SSRIs block the serotonin transporter (SERT) at the presynaptic membrane. This prevents the reuptake of released serotonin, thereby increasing its concentration and the duration of its action in the synaptic cleft.

SSRI medication mechanism diagram

Medical uses / Effects

[edit]

Depression severity

[edit]

A 2010 patient-level meta-analysis pooled six placebo-controlled trials in adult outpatients (718 patients) that did not drop early placebo responders before randomization. Three trials used the SSRI paroxetine and three the tricyclic imipramine. The drug-placebo difference grew with baseline severity. Below a Hamilton depression score of 23 the effect size was under Cohen d = 0.20, and the difference reached the NICE threshold for clinical significance only at a baseline score of 25.[7] The severity pattern held for both drug classes. Few patients scored 13 or lower at intake, so the data say little about the mildest cases.[8]

Treatment-resistant depression

[edit]

A 48-week pramipexole augmentation trial in treatment-resistant depression found benefit when dopamine signaling was raised alongside continued SSRI therapy, contrasting with serotonin-only strategies.[9]

Triiodothyronine (liothyronine, T3) is another augmenter used after antidepressant failure. In STAR*D level 3, T3 was at least as effective as lithium on remission and better tolerated;[10] a single case report (n=1) described PHQ-9 remission when T3 was added to an SSRI-containing regimen (fluoxetine plus bupropion and aripiprazole) after multiple prior failures.[11] See Depression and Triiodothyronine.

"Because it hasn’t been possible to provide evidence to support the idea that serotonin is a mood elevator happy hormone, the industry has looked for some way to explain the therapeutic benefit that they claim. They have generally settled on the idea that the SSRIs, after several weeks of use, increase the synthesis of the progesterone metabolite allopregnanolone, in the brain. That does happen, but the synthesis of those defensive steroids is also increased by any injury to the brain"[12] - Ray Peat

The serotonin hypothesis, chemical imbalance story, and its genetic basis do not hold. SSRIs mainly numb; the defensive rise in brain allopregnanolone is the main plausible benefit. Meyer et al. (2004) found no relationship between striatal serotonin-transporter occupancy and how much patients improved on the Hamilton scale.[13]

An evolutionary review argues serotonin transmission is elevated in depression and that the serotonergic system evolved to regulate energy; by raising extracellular serotonin, SSRIs disrupt energy homeostasis and often worsen symptoms (including ruminative processes) during acute treatment, with later symptom reduction attributed to compensatory homeostatic responses rather than the direct reuptake block.[14] Research shows there is no convincing evidence that depression is associated with, or caused by, lower serotonin concentrations or activity.[15]

In SmithKline Beecham Study 329 (275 adolescents with major depression), the 2001 JAACAP report described paroxetine as generally well tolerated and effective for adolescent major depression.[16] A 2015 RIAT reanalysis of the same protocol and clinical study reports found neither paroxetine nor imipramine differed from placebo on any prespecified primary or secondary efficacy outcome, with clinically significant increases in harms including suicidal ideation and behaviour in the paroxetine arm.[17] The Study 329 archive documents that the published paper was ghostwritten for GSK and contrasts the original effective / well-tolerated framing with the restored finding of no efficacy plus serious adverse effects including hostility, insomnia, and akathisia.[18]

Autopsy of suicide victims show high serotonin levels.[19][20]

Side / Adverse effects

[edit]

Three months of antidepressant treatment (mainly escitalopram) reduced affective empathy and empathy-related brain activity in depressed patients, while baseline depression itself showed no empathy deficit, implicating the drugs, not the illness, in blunted empathic responding; the effect was not explained by general blunting of negative affect, since self-experienced pain ratings did not change.[21]

Sexual adverse effects

[edit]

Raised synaptic serotonin can blunt genital sensation, nitric oxide-dependent vasodilation for genital blood flow, and dopamine-mediated reward pathways involved in sexual desire. Among women taking antidepressants, problems with sexual desire were reported in 72%, arousal in 83%, and orgasm in 42%.[22] In a Spanish prospective study of 1,022 outpatients with previously normal sexual function, 57% had decreased libido, 57% delayed orgasm or ejaculation, 46% no orgasm or ejaculation, and 31% erectile dysfunction or decreased vaginal lubrication.[23] In a FAERS disproportionality analysis covering about 6.6 million SSRI-linked adverse-event reports (2004–2025 Q1), erectile dysfunction was the most frequently reported male sexual adverse event across six SSRIs, with the strongest reporting signals for escitalopram and citalopram; FAERS cannot establish causality or comparative incidence.[24] Chronic escitalopram in rats reduced erectile responses to cavernosal nerve stimulation and lowered nitric oxide bioavailability through higher NADPH oxidase activity.[25]

Post-SSRI Sexual Dysfunction

[edit]

Post-SSRI Sexual Dysfunction (PSSD) is sexual dysfunction that continues after an SSRI, SNRI, or related serotonergic antidepressant is stopped, including genital anesthesia, pleasureless or weak orgasm, loss of libido, and erectile dysfunction.[26][27] Reviews separate PSSD from sexual dysfunction caused by ongoing depression, because restarting the same drug class can worsen an iatrogenic syndrome.[27]

In May 2019 the European Medicines Agency PRAC agreed that SSRI and SNRI product information should warn that sexual dysfunction can continue after discontinuation;[28] an EMA EudraVigilance analysis of antidepressants and persistent sexual dysfunction informed that labeling review.[29]

Case series include 300 international enduring sexual-dysfunction reports after serotonergic antidepressants (and related drugs)[30] and 86 Netherlands Lareb reports of persistent sexual dysfunction after SSRI withdrawal.[31] One Israeli HMO cohort estimated irreversible PSSD at 1 in 216 treated males (0.46%) under strict filters; broader incidence remains hard to quantify.[32][33] Mechanism hypotheses (epigenetic change, 5-HT1A downregulation, dopamine–serotonin imbalance) are speculative; no definitive treatment is established.[26]

Violent crime

[edit]

In Tobin v. SmithKline Beecham (2001), a Wyoming jury found GlaxoSmithKline 80% responsible for the 1998 killing of Donald Schell's wife, daughter, and infant granddaughter, followed by his own suicide, hours after he started Paxil. The jury awarded $6.4 million in damages.[34]

In a Swedish registry cohort of 785,337 SSRI-treated adults, antidepressant use associated with 26% higher odds of violent crime; elevated risk persisted up to 12 weeks after discontinuation and was strongest in patients with prior convictions.[35] Ketamine's rapid antidepressant PET profile (more 5-HT1B receptors, less serotonin release, more dopamine) contrasts with chronic SSRI-driven synaptic serotonin elevation.[36] Genetic loss of the serotonin transporter produced chronic anxiety and impaired fear extinction in mice, mirroring the elevated synaptic serotonin expected from SSRI therapy.[37] Mild chronic serotonin syndrome from continued SSRI therapy presented with nonspecific symptoms and did not resolve until serotonergic drugs were stopped, with risk of acute escalation after dose changes.[38] All six major SSRIs inhibited gonadal testosterone and DHT synthesis and lowered adrenal DHEA and progesterone in vitro, acting as endocrine disruptors beyond central serotonin reuptake blockade.[39] A single-blind, crossover study in 8 healthy male volunteers found that a 20-mg citalopram infusion given intravenously over 30 minutes in the early afternoon, with saline placebo control, significantly increased plasma prolactin and cortisol; the growth hormone surge after saline was inhibited after citalopram, except in one subject with pronounced side effects. This was an acute intravenous probe in healthy men, not chronic oral treatment and not evidence that people with depression usually have high prolactin.[40] Selective serotonin reuptake inhibitors were epidemiologically linked to microscopic colitis; experimental serotonin elevation impaired gut autophagy and worsened colitis severity.[41] Eric Harris, one of the two Columbine High School shooters (1999), had therapeutic levels of fluvoxamine (Luvox), an SSRI he had been prescribed for about a year, in his system at autopsy; toxicology found no other substances.[42] A single case does not establish causation; it is the kind of individual data point the Swedish registry association would predict.

In 2010, an inquest into the death of 22-year-old Shane Clancy, who fatally stabbed 22-year-old Sebastian Creane before killing himself in Bray, Ireland, in August 2009, returned an open verdict. The pathologist found toxic levels of citalopram, an SSRI Clancy had been prescribed weeks earlier, in his system at autopsy.[43][44]

Learning and behavioral control

[edit]

Week-long citalopram shifted human reinforcement learning toward punishment and away from reward in computational models, without improving net decision quality.[45]

Prenatal and neonatal neurodevelopment

[edit]

Perinatal fluoxetine combined with maternal immune activation synergistically altered offspring neurobiology and behavior in a model relevant to autism risk.[46] Perinatal fluoxetine impairs prefrontal excitatory synapse maturation via 5-HT2A and 5-HT7 receptor signaling, providing a direct serotonergic mechanism for SSRI-associated offspring brain hyperexcitability.[47]

Cardiac valve toxicity

[edit]

Impaired serotonin-transporter activity in mitral-valve cells promoted myxomatous degeneration and regurgitation, directly linking reduced SERT function (the SSRI target) to structural heart-valve disease.[48]

Neonatal behavioral toxicity

[edit]

Neonatal fluoxetine exposure increased adult anxiety and forced-swim immobility in rats, whereas 5-HT7 antagonism blocked fluoxetine-induced behavioral changes without mimicking antidepressant benefit.[49]

Chronic fatigue

[edit]

High-dose fluoxetine for 4 weeks produced intra- and extracellular serotonin spillover in the dorsal raphe nuclei of mice, with ME/CFS-like fatigue (rota-rod, fatigue rotating wheel, home-cage activity), nest-building malaise, plantar pain sensitivity, open-field anxiety-like behavior, and blunted HPA-axis corticosterone responses to exercise; the fatigue-like rota-rod deficit was abolished after 6 weeks of fluoxetine withdrawal. A 5-HT synthesis inhibitor (pCPA) reversed fluoxetine-induced fatigue and nest-building deficits. CRISPR-mediated Htr1a (5-HT1A) knockdown in the dorsal raphe reproduced fatigue, pain hypersensitivity, anxiety-like behavior, and lower plasma corticosterone. The paper frames this as animal evidence for the clinical hyper-serotonergic hypothesis of ME/CFS (low 5-HT1A or SERT binding potential on PET), not as proof that clinical SSRI doses cause human ME/CFS.[50] In isolated pig brain mitochondria, escitalopram, fluvoxamine, sertraline, and paroxetine inhibited electron transport chain complexes I and IV at 50 and 100 umol/L; complex II+III activity fell with all four. Complex I-linked respiration fell under the same SSRIs (paroxetine and fluvoxamine mainly at the highest concentrations); complex II-linked respiration was spared. All four also inhibited MAO-A and MAO-B more potently than bupropion or trazodone in the same assays.[51]

Cardiac toxicity

[edit]

SSRI exposure suppresses mitochondrial respiration and ATP production in human stem-cell cardiomyocytes and cardiac organoids, disrupting sarcomere organization.[52]

Hyponatremia

[edit]

In a Swedish self-controlled study of first-time SSRI or venlafaxine users, the odds of profound hyponatremia were about four times higher in the first three months after starting than in the same person's untreated periods. After a year of use, the excess was no longer significant.[53] https://x.com/pikeypilled/status/1884237602859147283

Weight and blood sugar

[edit]

The metabolic evidence for SSRIs is much weaker than for antipsychotics, and it is mostly observational. A meta-analysis of antidepressant trials and studies found most SSRIs had little effect on weight in the short term; fluoxetine caused some early weight loss, paroxetine was among the drugs most linked to weight gain, and differences grew with longer use.[54] In a UK primary-care cohort of nearly 300,000 adults followed for ten years, people prescribed any antidepressant gained 5% or more of their body weight about a fifth more often than non-users, though confounding could not be ruled out.[55] A systematic review of mostly observational studies linked antidepressant use with type 2 diabetes, but results varied by drug and causation was not established.[56] Olanzapine, by contrast, raised insulin and lowered insulin sensitivity in healthy volunteers within nine days in a randomized trial.[57]

If they increase your exposure to serotonin or decrease your adrenaline, they'll slow your metabolic rate and make it harder to burn calories.

— Ray Peat[58]

Luteal-phase dosing for PMDD

[edit]

For premenstrual dysphoric disorder (PMDD) and severe PMS, expert guidelines endorse intermittent SSRI dosing restricted to the late luteal phase (from ovulation, or from about 14 days before menses, through menstruation onset) as an alternative to continuous daily dosing, alongside continuous and symptom-onset regimens.[59] Critics note that repeatedly starting and stopping an SSRI each cycle, on top of the hormone swings luteal-phase dosing is meant to treat, has not been specifically followed up for suicidality risk; this concern is anecdotal/expressed on social media, not itself backed by a dedicated safety study.[60]

Some harms stay under-recognized because of deliberate withholding of information, black-box warnings that understate risk, and clinical data kept from the public.

  • Inability to feel love: Selective serotonin reuptake inhibitors were found to reduce the intensity and duration of feelings of love[61]
  • Learned helplessness: No drive to exit a toxic situation
  • Emotional numbness: Anhedonia, decreased empathy
  • Depersonalization
  • Cognitive decline: Faster cognitive decline, 35% increased risk of severe dementia, earlier death for dementia patients [62]
    • Symptoms also include: confusion, distorted thinking, convulsions, amnesia, brain-zaps
  • Bone density loss: In the SWAN cohort of midlife women, starting an SSRI went with a fracture risk about 77% higher than starting no antidepressant; women starting other antidepressants showed no increase.[63] Fluoxetine directly blocked osteoblast differentiation and mineralization during fracture healing in mice.[64] SSRI users had roughly twice the failure risk of dental implants that had already integrated with bone in a clinical cohort.[65]

A few years ago, the "serotonin reuptake inhibitor" antidepressants, already known to increase prolactin by increasing the effects of serotonin, were found to be causing osteoporosis after prolonged use.

— Ray Peat[66]
  • All-cause mortality. 18% increase
  • Bipolar disorder: Significantly raises the risk
    • Studies: *** SSRIs associated with a 7.7% annual rate of new bipolar diagnoses (tripling the baseline rate).[67]
      • 60% had their first manic episode after starting antidepressants for depression.[68]
      • 1 of 184 hospitalized patients on SSRIs developed mania and 8 became psychotic
        • 8% of 533 Yale admissions were for antidepressant-caused mania/psychosis.[69]
  • Violence: ** A 2020 Swedish register-based study found that SSRI use is associated with an increased risk of violent crime convictions persisting during treatment and up to 12 weeks after discontinuation[70],
      • Raised serotonin itself even without supplementation is proven to increase violent tendencies[71]
      • An earlier Swedish register cohort of 856,493 people prescribed SSRIs found the same age split: an overall 19% higher rate of violent crime conviction while on the drug versus off it in the same individuals, concentrated almost entirely in the 15-24 age group, where the rate was 43% higher. No significant association appeared in the 25-34, 35-44, or 45-and-older groups.[72]
      • A meta-analysis built from drug-company clinical study reports of placebo-controlled trials found no significant increase in suicidality or aggression in adults. In children and adolescents, antidepressants roughly doubled the risk of both suicidality and aggressive behavior.[73]
  • Suicide:
    • Restored Study 329 data showed clinically significant increases in suicidal ideation and behaviour on paroxetine, plus hostility, insomnia, and akathisia among serious adverse effects understated when many events were coded as "emotional lability" in the 2001 report.[17][18]
    • In a trial, SSRIs doubled the risk of harms related to suicidality and violence in adult healthy volunteers with no mental disorder.[74]
    • Study of 20 mentally healthy volunteers reported that Zoloft made 2 become suicidal, one close to actually committing suicide, both of whom remained deeply disturbed for months.[75]
    • Germany's drug regulator, the BGA, reviewed Lilly's fluoxetine application in 1984 and counted suicide attempts in about 1 in 90 treated patients, even though the trials had excluded patients at risk of suicide. The reviewer's summary opinion rated the drug "totally unsuitable for the treatment of depression."[76]
    • The BGA commission did not accept the registration in January 1985, and suicidal risk was one of its two main concerns.[77]
    • In February 1985 the BGA gave notice of its intent to refuse registration, because the drug's agitating effect started before its mood-lifting effect and so raised the risk of suicide. Lilly had three months to remedy the deficiencies or withdraw and reapply.[78]
    • A 1985 Lilly memo on a working session with the company's German consultant recorded suicide attempts as more frequent on fluoxetine than on imipramine, an older antidepressant. It rated the benefit/risk balance "not unequivocally positive."[79]
  • Antidepressant Withdrawal Syndrome[80]

New Zealand survey on 1,829 patients: 62% reported sexual difficulties, 60% felt emotionally numb, 52% felt not like themselves, 39% cared less about others, 47% had experienced agitation and 39% had experienced suicidal ideation.[81]

Heart valve fibrosis

[edit]

Long-term SSRI exposure correlates with earlier mitral-valve surgery; serotonin transporter genotype and pharmacologic SERT blockade promote mitral thickening in animal models.[82]

Tinnitus

[edit]

Raising synaptic serotonin with SSRIs can worsen tinnitus by hyperactivating cochlear-nucleus fusiform neurons; patients with hearing loss or tinnitus may need caution with serotonergic antidepressants.[83] Insomnia, nightmares, ‘Fuzzy’/‘zombie,’ jaw grinding, sweating, blurred vision, constipation, disturbed/restless sleep, anxiety, heart palpitations, difficulty thinking, fatigue/exhaustion, strange/vivid dreams, stiff muscles/joints,’ mania, excessive yawning, panic attacks, memory loss, decreased motivation, night sweats, decreased appetite, feeling agitated, shaky or anxious, indigestion, stomach aches and diarrhea.[81]

Pregnancy adverse effects

[edit]

In mother-infant pairs, gestational SRI exposure cut median maternal platelet serotonin about 88% (17.0 vs 141 ng/mL in non-exposed mothers; roughly eight-fold lower) and infant cord platelet serotonin about 73% (21.0 vs 78.8 ng/mL; roughly four-fold lower). Depression without SRI did not change platelet serotonin. Lower maternal and infant platelet serotonin tracked more immature fetal movement quality on ultrasound, a restless or fidgety pattern resembling neonatal adaptation syndrome.[84]

In a Welsh population cohort (observational) followed through linked primary care, maternity and school records, prenatal antidepressant exposure, mostly SSRIs, went with higher odds of special educational need. Untreated maternal depression also raised the odds. Among mothers with depression, antidepressants added about 3 cases of special educational need per 100 children. Odds also rose for autism, behavioral-emotional-social difficulties and ADHD. The treated-versus-untreated depression difference reached significance only for learning and behavioral-emotional-social difficulties. It was not significant for autism or ADHD. SSRIs alone added fewer cases over untreated depression than tricyclics or SNRIs. The cohort had no depression-severity data and no sibling comparison, so confounding by indication remains open.[85]

In Korean infertility-care claims (2017-2023), women on ongoing antidepressant treatment had about half the adjusted pregnancy rate of non-depressed controls, and a lower rate still when treatment started after infertility care began; past-treated depressed women did slightly better than controls. Antidepressant-treated pregnancy cohorts had higher odds of spontaneous abortion than non-depressed controls; associations cannot separate medication effects from illness burden or confounding by indication.[86]

shorter babies with smaller heads in mothers taking them during pregnancy[87]

30% of babies will also experience “neonatal adaptation syndrome” (withdrawals) post birth.[88]

  • Impaired energy signaling in dorsal hippocampus causes depression/anxiety in stressed mice.[89]
  • Glucose hypometabolism in bilateral insula and cingulate gyrus in depressed individuals.[90]
  • No consistent association between low serotonin and depression.[91]
  • Declining basal metabolic rates and body temperatures not due to reduced activity.[92]
  • Doctors receiving payments prescribe tied drugs 58% more; pattern for 46/50 drugs.[93]
  • Positive association between payments and prescriptions in 30/36 studies.[94]
  • Reclassify 'suicide attempt' to 'overdose' and 'suicidal ideation' to 'depression'. Claude Bouchy memo, 1990 (Exhibits 117-118, Forsyth v. Eli Lilly)[95]
  • Evidence of being misled on fluoxetine safety.[96]
  • Large-scale underreporting of suicidality in fluoxetine data.[97]
  • 50,000 excess suicides attributable to Prozac since launch.[98]
  • Negative benefit-risk balance for Prozac in children under 18.[99]
  • Serotonergic antidepressants most implicated in violence reports.[100]

Withdrawal syndrome (FAERS)

[edit]

In a FAERS disproportionality analysis (2004 Q1–2023 Q3; 94,370 withdrawal-syndrome reports), antidepressants ranked among the top positive-signal classes alongside opioids and antianxiety drugs.[101] Among antidepressants with notable ROR intensities were paroxetine 29.36 (28.59–30.15), duloxetine 17.41 (17.00–17.83), and venlafaxine 10.32 (9.98–10.67); paroxetine ranked fourth overall by ROR, above several opioids in that ranking.[102] ROR reflects reporting disproportion in spontaneous FAERS data, not the prevalence of withdrawal among antidepressant users. See Drug withdrawal.

Tapering off

[edit]

"It takes time to adapt to decreasing those drugs, keeping sugar up and inflammation down, including bag breathing, should help. Starting with a little, a sixth or fourth of a tablet, of cynoplus in the evening would be the best way to try it." - Ray Peat[103]

Getting the tapering off right is vital, having high metabolism and the right hormonal balance lessens the "fall".

Keeping the metabolic rate and cholesterol up is important, so that repair and adaptation will be quick. Progesterone reduces pain and anxiety, and pregnenolone would be the most convenient supplement for men, but it's hard to find products without allergens. Combining progesterone and DHEA or testosterone can produce the stabilizing effect without suppressing the libido. Benadryl and cyproheptadine are probably both helpful. Withdrawal from morphine and SSRIs and migraine involve some similar processes.

It depends on how much pregnenolone you can assimilate. People would use progesterone in amounts needed to stop the withdrawal symptoms, but pregnenolone doesn't have the powerful effects of progesterone, even in multi-gram quantities, so it's just a matter of seeing what it can do. As I understand the mechanism (migraine, withdrawal, etc.), estrogen-histamine-serotonin rise on a background of hypothyroid liver malfunction, cytomel (and/or sugar, selenium, B vitamins) allows the liver and other detoxifying systems to lower them, and the lower they are, the less progesterone or pregnenolone it takes to block the symptoms.[104]

SSRIs tend to increase stress hormones, so an anti-stress program is central to withdrawal. People have withdrawn from SSRIs and other addictive drugs using progesterone, coffee, thyroid, and a high-calcium diet.[105]

Linear tapering

[edit]
  • Fixed dose reductions (e.g., 50% every 2-4 weeks) down to minimum therapeutic dose
  • Simple, guideline-recommended, but can cause intense withdrawal symptoms (up to 78% in short tapers) due to abrupt SERT occupancy drops
    • Often leads to relapse misdiagnosis; success variable.[106]

Discontinuation-induced relapse, misdiagnosed as relapse of illness

[edit]

A meta-analysis of 27 placebo-controlled discontinuation studies (3,037 patients) found antidepressant discontinuation raised the monthly relapse rate more than threefold compared to continued treatment (6.24%/month vs. 1.85%/month), and roughly doubled the 12-month relapse risk (44.8% vs. 19.5%).[107] The same pattern, a drug-withdrawal relapse mistaken for the return of the original condition rather than recognized as a withdrawal effect of the drug itself, recurs across antidepressants, antipsychotics, and mood stabilizers, and this risk is not typically included in the informed consent patients receive before starting or stopping these drugs.[108]

Hyperbolic tapering

[edit]
  • Method for discontinuing SSRIs, proposed by Dr. Mark Horowitz in 2019.
  • Larger initial dose reductions followed by progressively smaller reductions to minimize withdrawal symptoms, contrasting with traditional linear tapering.

Rationale

[edit]

Based on the hyperbolic relationship between SSRI dosage and serotonin transporter (SERT) occupancy. Even small doses maintain significant SERT occupancy, necessitating gradual reductions at lower doses to avoid abrupt drops that trigger severe withdrawal effects.

Comparison with linear tapering

[edit]

Linear tapering reduces doses by fixed amounts, which can lead to intense withdrawal symptoms at lower doses. Hyperbolic tapering mitigates this by aligning dose reductions with the drug's pharmacodynamic effects, resulting in milder and more manageable symptoms.

Implementation

[edit]

The method recommends starting with larger reductions and slowing down as doses decrease, potentially extending over six to twelve months or longer. Options include using liquid formulations, compounding pharmacies, pill-cutting, or bead-counting for precise dosing. Specific schedules, such as reducing escitalopram from 10mg to 0mg in steps like 5mg, 3mg, 1.5mg, 1mg, 0.5mg, and 0.25mg, are highlighted as effective.

Managing withdrawal symptoms

[edit]

Supportive measures are emphasized, including high-dose magnesium, thiamine (with caution on forms like TTFD initially), taurine, glycine, and L-theanine to balance GABA/glutamate and reduce excitotoxicity. Sodium supplementation is advised to counter hyponatremia, potentially using skimmed milk with salt. Avoiding additional serotonin-modulating agents during tapering is recommended to clearly identify withdrawal effects.[109]

Potential challenges and considerations

[edit]

Prolonged tapering might sometimes exacerbate symptoms in certain cases, leading to protracted withdrawal. A study advises monitoring for misinterpretation of withdrawal as relapse and suggests short term fluoxetine substitution for high-risk SSRIs, though fluoxetine is not self-tapering despite its long half-life.

Outcomes and evidence

[edit]

Observational data indicates hyperbolic tapering is associated with limited, rate-dependent withdrawal symptoms, with success rates around 72% in case studies[110]. It stresses the importance of personalized schedules and professional guidance to achieve antidepressant-free status without significant issues.

Brands and sources

[edit]

Brands

[edit]
  • Zoloft (sertraline)
  • Lexapro (escitalopram)
  • Prozac (fluoxetine)
  • Celexa (citalopram),
  • Paxil (paroxetine),
  • Luvox (fluvoxamine)

References

[edit]
  1. ↑ "Serotonin, depression, and aggression: The problem of brain energy," Ray Peat article
  2. ↑ "Serotonin: Effects in disease, aging and inflammation," Ray Peat article
  3. ↑ "Can Improving Overall Health Affect Personality Narcissism," Low Tox in Forum thread
  4. ↑ "Antidepressant Use Among Adults: United States, 2015-2018", NCHS Data Brief No. 377, 2020
  5. ↑ "Characteristics of Adults Aged 65 and Over", NCHS Data Brief No. 528, 2025
  6. ↑ Progesterone reverses CUMS depression via NLRP3, Behav Brain Res. 2025. doi:10.1016/j.bbr.2025.115879.
  7. ↑ Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J. "Antidepressant drug effects and depression severity: a patient-level meta-analysis," JAMA. 2010;303(1):47-53. doi:10.1001/jama.2009.1943. PMID 20051569. PMC3712503.
  8. ↑ Fournier JC, et al. "Antidepressant drug effects and depression severity: a patient-level meta-analysis," JAMA. 2010;303(1):47-53. PMC3712503. Methods, results and limitations.
  9. ↑ Browning M, et al. "Pramipexole for treatment-resistant depression," Lancet Psychiatry. 2025. doi:10.1016/S2215-0366(25)00194-4. PMID 40602411.
  10. ↑ Nierenberg AA, Fava M, Trivedi MH, et al. "A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report," Am J Psychiatry. 2006;163(9):1519-30. PMID 16946176.
  11. ↑ Al Jumaili WA, Chaudhary N, Al Gburi NA, Al Jumaili YA. "Triiodothyronine Augmentation for Treatment-Resistant Depression," Prim Care Companion CNS Disord. 2025;27(1):24cr03822. doi:10.4088/PCC.24cr03822. PMID 39919223.
  12. ↑ "Ray Peat on progesterone"
  13. ↑ Meyer et al., "Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11CDASB Positron Emission Tomography Study," American Journal of Psychiatry, 2004]
  14. ↑ Andrews PW, Bharwani A, Lee KR, Fox M, Thomson JA Jr. "Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response," Neurosci Biobehav Rev. 2015;51:164-188. doi:10.1016/j.neubiorev.2015.01.018. PMID 25625874.
  15. ↑ "The serotonin theory of depression: a systematic umbrella review of the evidence - Molecular Psychiatry"
  16. ↑ Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al. "Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial," J Am Acad Child Adolesc Psychiatry. 2001;40(7):762-772. PMID 11437014.
  17. ↑ 17.0 17.1 Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, et al. "Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence," BMJ. 2015;351:h4320. doi:10.1136/bmj.h4320. PMID 26376805.
  18. ↑ 18.0 18.1 "Study 329," study329.org.
  19. ↑ Bach H et al., "Elevated serotonin and 5-HIAA in the brainstem and lower serotonin turnover in the prefrontal cortex of suicides," Synapse (New York, N.Y.), 2014
  20. ↑ Korpi et al., "Serotonin and 5-Hydroxyindoleacetic Acid in Brains of Suicide Victims: Comparison in Chronic Schizophrenic Patients With Suicide as Cause of Death," Archives of General Psychiatry, 1986
  21. ↑ Rütgen M, Pletti C, Tik M, Kraus C, Pfabigan DM, Sladky R, Klöbl M, Woletz M, Vanicek T, Windischberger C, Lanzenberger R, Lamm C. "Antidepressant treatment, not depression, leads to reductions in behavioral and neural responses to pain empathy," Transl Psychiatry. 2019;9(1):164. doi:10.1038/s41398-019-0496-4. PMID 31175273.
  22. ↑ Lorenz T, Rullo J, Faubion S. "Antidepressant-induced female sexual dysfunction," Mayo Clin Proc. 2016;91(9):1280–1286. PMID 27594188.
  23. ↑ Montejo AL et al., "Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction," The Journal of clinical psychiatry, 2001
  24. ↑ Li S, et al. "Male sexual dysfunction associated with selective serotonin reuptake inhibitors (SSRIs): a pharmacovigilance disproportionality analysis of FAERS data," J Affect Disord. 2026. PMID 41662926.
  25. ↑ Kassan M, et al. "Chronic escitalopram treatment induces erectile dysfunction by decreasing nitric oxide bioavailability," J Sex Med. 2013. PMID 24242893.
  26. ↑ 26.0 26.1 Bala A, Nguyen HMT, Hellstrom WJG. "Post-SSRI Sexual Dysfunction: A Literature Review," Sex Med Rev. 2018;6(1):29-34. doi:10.1016/j.sxmr.2017.07.002. PMID 28778697.
  27. ↑ 27.0 27.1 Peleg LC, Rabinovitch D, Lavie Y, et al. "Post-SSRI Sexual Dysfunction (PSSD): Biological Plausibility, Symptoms, Diagnosis, and Presumed Risk Factors," Sex Med Rev. 2022;10(1):91-98. doi:10.1016/j.sxmr.2021.07.001. PMID 34627736.
  28. ↑ "PRAC recommendations on signals adopted at the 13-16 May 2019 PRAC meeting," European Medicines Agency, EMA/PRAC/265221/2019.
  29. ↑ "Antidepressants and persistent sexual dysfunction: EudraVigilance analysis," EMA/132684/2019, 20 February 2019.
  30. ↑ Healy D, Le Noury J, Mangin D. "Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases," Int J Risk Saf Med. 2018;29(3-4):125-134. doi:10.3233/JRS-180744. PMID 29733030. PMC6004900.
  31. ↑ Chinchilla Alfaro K, van Hunsel F, Ekhart C. "Persistent sexual dysfunction after SSRI withdrawal: a scoping review and presentation of 86 cases from the Netherlands," Expert Opin Drug Saf. 2022;21(4):553-561. doi:10.1080/14740338.2022.2007883. PMID 34791958.
  32. ↑ Ben-Sheetrit J, Hermon Y, Birkenfeld S, et al. "Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants," Ann Gen Psychiatry. 2023;22:15. doi:10.1186/s12991-023-00447-0. PMID 37085865. PMC10122283.
  33. ↑ Healy D, Mangin D. "Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence," Epidemiol Psychiatr Sci. 2024;33:e40. doi:10.1017/S2045796024000441. PMID 39289881.
  34. ↑ "U.S. court awards $6.4-million in Paxil deaths case," The Globe and Mail.
  35. ↑ Lagerberg T, Vieta E, et al. "SSRIs and violent criminality," Eur Neuropsychopharmacol. 2020. doi:10.1016/S0924-977X(20)30104-8.
  36. ↑ Lundberg J, et al. "Ketamine, 5-HT1B, and dopamine," Transl Psychiatry. 2020. doi:10.1038/s41398-020-0844-4.
  37. ↑ Bearer CF, et al. "SERT deletion and persistent anxiety," Neuroimage. 2020. doi:10.1016/j.neuroimage.2020.117281.
  38. ↑ Prakash S, et al. "Chronic serotonin syndrome," World J Psychiatry. 2021. doi:10.5498/wjp.v11.i4.124.
  39. ↑ Hansen C, et al. "SSRIs decrease androgens and progestogens," Toxicol In Vitro. 2017. doi:10.1016/j.tiv.2017.02.001.
  40. ↑ Seifritz E, Baumann P, Muller MJ, Annen O, Amey M, Hemmeter U, Hatzinger M, Chardon F, Holsboer-Trachsler E. "Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe," Neuropsychopharmacology. 1996;14(4):253-263. PMID 8924193. doi:10.1016/0893-133X(95)00117-V. Eight healthy male volunteers; single-blind, saline-controlled crossover; 20 mg IV over 30 minutes; significant prolactin and cortisol increases and inhibition of the saline-associated GH surge.
  41. ↑ Haq S, et al. "Serotonin disrupts autophagy in gut inflammation," Sci Adv. 2021. doi:10.1126/sciadv.abi6442.
  42. ↑ "Eric Harris's Autopsy Report," School Shooters.info.
  43. ↑ "Jury delivers open verdict in Clancy death inquest," The Irish Times, 2010.
  44. ↑ "Open verdict in Shane Clancy inquest," RTÉ News, 2010.
  45. ↑ Michely J, et al. "Serotonin and asymmetric reinforcement learning," Commun Biol. 2022. doi:10.1038/s42003-022-03690-5.
  46. ↑ Zengeler KA, Lukens JR, et al. "SSRI and maternal inflammation in offspring neurobiology," Brain Behav Immun. 2023. doi:10.1016/j.bbi.2022.10.024.
  47. ↑ Oh WC, et al. "Serotonin and prefrontal synapse maturation," Nat Commun. 2024. doi:10.1038/s41467-024-45734-w.
  48. ↑ Castillero E, et al. "Serotonin transporter activity in mitral valve disease," Sci Transl Med. 2023. doi:10.1126/scitranslmed.adc9606.
  49. ↑ Goumon Y, et al. "5-HT7 blockade and SSRI behavioral effects," Neuropsychopharmacology. 2011. doi:10.1038/npp.2011.13. PMID 21326194.
  50. ↑ Lee JS, Kang JY, Park SY, Hwang SJ, Bae SJ, Son CG. "Central 5-HTergic hyperactivity induces myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-like pathophysiology," J Transl Med. 2024;22:34. doi:10.1186/s12967-023-04808-x. PMID 38191373. PMC10773012.
  51. ↑ Lupták M, Fišar Z, Hroudová J. "Different Effects of SSRIs, Bupropion, and Trazodone on Mitochondrial Functions and Monoamine Oxidase Isoform Activity," Antioxidants (Basel). 2023;12(6):1208. doi:10.3390/antiox12061208. PMID 37371937.
  52. ↑ Shen Y, et al. "SSRI cardiac mitochondrial toxicity," Commun Biol. 2025. doi:10.1038/s42003-025-08168-8.
  53. ↑ Issa I, Skov J, Falhammar H, Roos M, Lindh JD, Mannheimer B. "The association of selective serotonin reuptake inhibitors and venlafaxine with profound hyponatremia," Eur J Endocrinol. 2025;193(1):179-187. doi:10.1093/ejendo/lvaf140. PMID 40627725. Erratum: doi:10.1093/ejendo/lvag157. Stockholm Sodium Cohort, 234,217 first-time users 2007-2017, individual as own control; profound hyponatremia = plasma sodium below 125 mmol/L. aOR 4.29 (95% CI 3.34-5.52) first 3 months; 10.06 (5.97-17.00) first 2 weeks; 1.30 (0.97-1.75) after 1 year. Incidence 6.5% in women aged 80 and over.
  54. ↑ Serretti A, Mandelli L. "Antidepressants and body weight: a comprehensive review and meta-analysis," J Clin Psychiatry. 2010;71(10):1259-1272. doi:10.4088/JCP.09r05346blu. PMID 21062615.
  55. ↑ Gafoor R, Booth HP, Gulliford MC. "Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study," BMJ. 2018;361:k1951. doi:10.1136/bmj.k1951. PMID 29793997.
  56. ↑ Barnard K, Peveler RC, Holt RI. "Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review," Diabetes Care. 2013;36(10):3337-3345. doi:10.2337/dc13-0560. PMID 24065841.
  57. ↑ Teff KL, Rickels MR, Grudziak J, et al. "Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease," Diabetes. 2013;62(9):3232-3240. doi:10.2337/db13-0430. PMID 23835329.
  58. ↑ Ray Peat, "Ask the Herb Doctor: Weight Gain", KMUD, 2013, 41:54
  59. ↑ Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C, Roberts DL, Yonkers K. "Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs," J Womens Health (Larchmt). 2006;15(1):57-69. doi:10.1089/jwh.2006.15.57. PMID 16417420.
  60. ↑ @Know_Yourself_H, X post, Aug 2026
  61. ↑ Babková J et al., "The Molecular Basis of Love," International journal of molecular sciences, 2025
  62. ↑ Mo M et al., "Antidepressant use and cognitive decline in patients with dementia: a national cohort study," BMC medicine, 2025
  63. ↑ Solomon DH, Ruppert KM, Lian Y, Neal-Perry G, Cauley JA, Burnett-Bowie SM. "The risk of fracture among women starting selective serotonin reuptake inhibitors," J Bone Miner Res. 2025;40(11):1238-1245. PMID 40757575. Observational cohort, 1,849 women. Any fracture per 100 person-years: SSRI starters 2.64, other antidepressant starters 0.80, non-users 1.21. Fully adjusted HR 1.77 (95% CI 1.15-2.74) vs no antidepressant.
  64. ↑ Bradaschia-Correa V, et al. "The Selective Serotonin Reuptake Inhibitor Fluoxetine Directly Inhibits Osteoblast Differentiation and Mineralization During Fracture Healing in Mice," J Bone Miner Res. 2017;32(4):821-833. PMID 27869327.
  65. ↑ Wu X, Al-Abedalla K, Rastikerdar E, et al. "Selective serotonin reuptake inhibitors and the risk of osseointegrated implant failure: a cohort study," J Dent Res. 2014;93(11):1054-1061. PMID 25186831. PMC4212463.
  66. ↑ Osteoporosis, aging, tissue renewal, and product science
  67. ↑ Suarez et al., "Association of Antidepressant Use During Pregnancy With Risk of Neurodevelopmental Disorders in Children," JAMA Internal Medicine, 2022
  68. ↑ El-Mallakh RS et al., "Use of antidepressants to treat depression in bipolar disorder," Psychiatric services (Washington, D.C.), 2002
  69. ↑ Breggin, P. R. (2009). Medication madness: The Role of Psychiatric Drugs in Cases of Violence, Suicide, and Crime. Macmillan.
  70. ↑ Lagerberg et al. "Associations between selective serotonin reuptake inhibitors and violent crime in adolescents, young, and older adults - a Swedish register-based study,", European Neuropsychopharmacology, 2020
  71. ↑ Moffitt TE et al., "Whole blood serotonin relates to violence in an epidemiological study," Biological psychiatry, 1998
  72. ↑ Molero Y, Lichtenstein P, Zetterqvist J, Gumpert CH, Fazel S. "Selective Serotonin Reuptake Inhibitors and Violent Crime: A Cohort Study," PLoS Med. 2015;12(9):e1001875. PMID 26372359.
  73. ↑ Sharma T, Guski LS, Freund N, Gøtzsche PC. "Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports," BMJ. 2016;352:i65. PMID 26819231. 70 double-blind placebo-controlled trials, 18,526 patients, 64,381 pages of clinical study reports (duloxetine, fluoxetine, paroxetine, sertraline, venlafaxine). Adults: suicidality OR 0.81 (0.51-1.28), aggression OR 1.09 (0.55-2.14). Children and adolescents: suicidality OR 2.39 (1.31-4.33), aggression OR 2.79 (1.62-4.81).
  74. ↑ "Systematic review of adverse effects of antidepressants in healthy volunteer studies | Cochrane Colloquium Abstracts"
  75. ↑ Healy, D. (2022). Let them eat prozac. In New York University Press eBooks. https://doi.org/10.18574/nyu/9780814790915.001.0001
  76. ↑ Eli Lilly, Bad Homburg (B. von Keitz). "Fluoxetine" memo of 25 May 1984 to J. Harper, S. A. Taurel and others, enclosing an English translation of the BGA medical comment on the fluoxetine application, unofficially received by Lilly. Litigation document, Bates Pz 281 1522–1526. PDF. Translation p. 2: 1,427 patients treated with the preparation. Translation p. 3: "During the treatment with the preparation 16 suicide attempts were made, 2 of these with success. As patients with a risk of suicide were excluded from the studies, it is probable that this high proportion can be attributed to an action of the preparation in the sence of an deterioration of the clinical condition." 16/1,427 = 1.1%. Translation p. 4, Summarizing opinion 2: "Considering the benefit and the risk, we think this preparation totally unsuitable for the treatment of depression."
  77. ↑ Eli Lilly telex, 29 January 1985, "RE: Fluoxetine registration". Litigation document, Bates Pz1124 1162. PDF: "We inofficially received our confirmation that fluoxetine was discussed by the Commission A at the BGA on January 21st. Two major concerns seem to be the reason that the registration was not accepted. Efficacy questioned ... Suicidal risk."
  78. ↑ Bundesgesundheitsamt (BGA), Berlin, letter signed Dr. U. Schmidt, 26 February 1985, "Application for registration of Fluctin (formerly Fluoxetin, Lilly) 20/40/60 capsules", Lilly English translation. Litigation document, Bates Pz1124 336–337. PDF. p. 1: "we intend to refuse the registration of the above mentioned drugs for the following reasons ... 2.1. The use of the preparations seems objectionable, as the increase in agitating effect occurs earlier than the mood elevating effect and therefore an increased risk of suicide exists." p. 2: "According to § 25 par. 4 AMG we herewith give you the opportunity to amend the before mentioned deficiencies within three month of the receipt of this letter."
  79. ↑ Schenk J (Eli Lilly, Bad Homburg). "Report on Fluoxetine Working Session", memo to S. Bandak, S. A. Taurel and others, fax header 3 April 1985 (the law-firm index dates it 1 April 1986). Fentress litigation exhibit "Weber 6", Bates Pz1124 229–231. PDF. Data reviewed included the "Analysis of pooled studies fluoxetine vs. imipramine vs. placebo (protocol no. 27)". p. 2: "Still not resolved is the fact that suicide attempts have been observed more frequently on fluoxetine as compared to imipramine"; "Benefit/risk ratio: Not unequivocally positive."
  80. ↑ "Therapeutics Initiative | [112 Antidepressant Withdrawal Syndrome"]
  81. ↑ 81.0 81.1 Read J et al., "Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants," Psychiatry research, 2014
  82. ↑ Jain R, et al. "Serotonin and mitral valve disease," Sci Transl Med. 2023. PMID 36599005.
  83. ↑ Tang ZQ, Trussell LO, et al. "Serotonin and tinnitus," Cell Rep. 2017. PMID 28834748.
  84. ↑ Salisbury AL, et al. "immature fetal movement," Neuropsychopharmacology. 2024. doi:10.1038/s41386-024-01923-1. PMID 39127823.
  85. ↑ McIlvride S, Rao N, Singh S, Nelson SM, Pell JP, Fleming M. "Prenatal exposure to maternal depression and antidepressants and neurodevelopmental outcomes: A population cohort study," PLoS Med. 2026;23(9):e1004658. doi:10.1371/journal.pmed.1004658. PMID 42809515. PMCID PMC13623103. Observational cohort, 167,447 children born 2009–2016, mean follow-up 5.68 years; 83.4% of exposure SSRIs. Special educational need: antidepressants adjusted OR 1.46 (95% CI 1.38–1.56); untreated depression adjusted OR 1.25. Predicted per 100: 20.0 unexposed, 23.6 untreated depression, 26.3 antidepressants without recorded depression, 26.5 treated depression; antidepressants added 2.9 per 100 (95% CI 1.7–4.1) with depression and 6.3 without. Autism adjusted OR 1.59; behavioral-emotional-social difficulties adjusted OR 1.70; ADHD adjusted HR 1.89. SSRIs alone added 2.0 per 100 over untreated depression; tricyclics and SNRIs 8.8 each.
  86. ↑ Shin SY, et al. "spontaneous abortion," Prog Neuropsychopharmacol Biol Psychiatry. 2026. doi:10.1016/j.pnpbp.2026.111911. PMID 42735740. Claims cohort; pregnancy sHR 0.53 (95% CI 0.48-0.58) ongoing treatment, 0.31 (95% CI 0.28-0.35) treatment started after infertility care, 1.10 (95% CI 1.03-1.18) past treatment, all vs non-depressed controls.
  87. ↑ Dubnov-Raz G et al., "Maternal use of selective serotonin reuptake inhibitors during pregnancy and neonatal bone density," Early human development, 2012
  88. ↑ "Antidepressants and Pregnancy: What to Know", Johns Hopkins Medicine
  89. ↑ https://www.sciencedaily.com/releases/2025/11/251126025315.htm.
  90. ↑ Fu C et al., "A combined study of (18)F-FDG PET-CT and fMRI for assessing resting cerebral function in patients with major depressive disorder," Experimental and therapeutic medicine, 2018
  91. ↑ "The serotonin theory of depression: a systematic umbrella review of the evidence - Molecular Psychiatry"
  92. ↑ Speakman JR et al., "Total daily energy expenditure has declined over the past three decades due to declining basal expenditure, not reduced activity expenditure," Nature metabolism, 2023
  93. ↑ "Doctors Prescribe More of a Drug If They Receive Money from a Pharma Company Tied to It"
  94. ↑ Mitchell AP et al., "Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic Review," Annals of internal medicine, 2021
  95. ↑ "Prozac Timeline Presented In The Forsyth V. Eli Lilly Trial"
  96. ↑ Lenzer "FDA to review "missing" drug company documents,", BMJ, 2004
  97. ↑ Lenzer J, "FDA to review "missing" drug company documents," BMJ (Clinical research ed.), 2005
  98. ↑ "Cambridge 02138 | Harvard Magazine"
  99. ↑ "prozac.childrenEU"
  100. ↑ "Prescription Drugs Associated with Reports of Violence Towards Others"
  101. ↑ Zhang Z, Yang Q, Chen M, Yang W, Wang Y. "Evaluating drug withdrawal syndrome risks through FAERS," Front Pharmacol. 2024;15:1385651. doi:10.3389/fphar.2024.1385651. PMID 39050751.
  102. ↑ Zhang Z, et al. "Evaluating drug withdrawal syndrome risks through FAERS," Front Pharmacol. 2024. doi:10.3389/fphar.2024.1385651. PMID 39050751.
  103. ↑ "Anti-Depressants," Ray Peat email exchange
  104. ↑ "Ray Peat Email Advice Depository," Low Tox in Forum thread, post #24432
  105. ↑ Ray Peat, "Ask the Herb Doctor: Tryptophan", KMUD, 2019-11-15.
  106. ↑ Horowitz MA et al., "Tapering of SSRI treatment to mitigate withdrawal symptoms," The lancet. Psychiatry, 2019
  107. ↑ Viguera AC, Baldessarini RJ, Friedberg J. "Discontinuing antidepressant treatment in major depression," Harv Rev Psychiatry. 1998;5(6):293-306.
  108. ↑ Robert Whitaker, Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America (Crown, 2010).
  109. ↑ @0xkda on X
  110. ↑ Groot et al., "Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study," Therapeutic Advances in Psychopharmacology, 2021